Therapies for scleroderma-related pulmonary arterial hypertension

Expert Review of Respiratory Medicine

Volumn 3, Issue 2, 2009, Pages 187-196

  Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelin receptor antagonist; Phosphodiesterase inhibitor; Prostaglandin; Pulmonary arterial hypertension; Scleroderma; Therapy

Indexed keywords

AMBRISENTAN; ANTIINFLAMMATORY AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMATINIB; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SILDENAFIL; SITAXSENTAN; SORAFENIB; UNIPROST; WARFARIN;

ANTICOAGULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; ECHOCARDIOGRAPHY; EXERCISE TEST; HUMAN; LOW DRUG DOSE; LUNG TRANSPLANTATION; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SURVIVAL; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

EID: 69949178696     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.5     Document Type: Review

References (92)

1. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115(5), 343-349 (1991).
2. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 352, 719-725 (1998).
3. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med. 107(2), 216-223 (1987).
4. Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43(12 Suppl.), S5-S12 (2004).
5. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron. Artery Dis. 16(1), 13-18 (2005).
6. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 109(2), 159-165 (2004).
7. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351(14), 1425-1436 (2004).
8. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123(2), 344-350 (2003).
9. Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 54(9), 3043-3050 (2006).
10. MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 40(4), 453-459 (2001).
11. Overbeek MJ, Lankhaar JW, Westerhof N et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur. Respir. J. 31(6), 1160-1166 (2008).
12. Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67(3), 737-744 (2000).
13. Lane KB, Machado RD, Pauciulo MW et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet. 26(1), 81-84 (2000).
14. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann. Intern. Med. 140(1), 37-50 (2004).
15. Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum. Dis. Clin. North Am. 29(2), 211-237 (2003).
16. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15(2), 202-205 (1988).
17. Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 48(8), 2246-2255 (2003).
18. Mayes MD. Scleroderma epidemiology. Rheum. Dis. Clin. North Am. 29(2), 239-254 (2003).
19. Silman A, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br. J. Rheumatol. 27(4), 286-290 (1988).
20. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch. Dermatol. Res. 283(6), 366-371 (1991).
21. Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 43(5), 596-602 (2004).
22. Murata I, Kihara H, Shinohara S, Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn. Circ. J. 56(10), 983-991 (1992).
23. Battle RW, Davitt MA, Cooper SM et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 110(6), 1515-1519 (1996).
24. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 124(6), 2098-2104 (2003).
25. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 29(4), 515-524 (1986).
26. Sacks DG, Okano Y, Steen VD, Curtiss E, Shapiro LS, Medsger TA Jr. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J. Rheumatol. 23(4), 639-642 (1996).
27. Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis. 62(11), 1088-1093 (2003).
28. Hachulla E, Gressin V, Guillevin L et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 52(12), 3792-3800 (2005).
29. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br. J. Rheumatol. 35(10), 989-993 (1996).
30. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 66(7), 940-944 (2007).
31. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106(12), 1477-1482 (2002).
32. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J. Rheumatol. 33(2), 269-274 (2006).
33. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 48(2), 516-522 (2003).
34. Allanore Y, Borderie D, Avouac J et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 58(1), 284-291 (2008).
35. Hsiao SH, Lee CY, Chang SM, Lin SK, Liu CP. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. J. Am. Soc. Echocardiogr. 19(5), 507-514 (2006).
36. Lee CY, Chang SM, Hsiao SH, Tseng JC, Lin SK, Liu CP. Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion. Echocardiography 24(2), 118-125 (2007).
37. Meune C, Avouac J, Wahbi K et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum. 58(6), 1803-1809 (2008).
38. Williams MH, Handler CE, Akram R et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur. Heart J. 27(12), 1485-1494 (2006).
39. Forfia PR, Mathai SC, Fisher MR et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 177(12), 1364-1369 (2008).
40. Williams MH, Das C, Handler CE et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92(7), 926-932 (2006).
41. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. 121(6), 409-415 (1994).
42. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346(12), 896-903 (2002).
43. Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 487-492 (2000).
44. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334(5), 296-302 (1996).
45. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40(4), 780-788 (2002).
46. Macchia A, Marchioli R, Marfisi R et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am. Heart J. 153(6), 1037-1047 (2007).
47. Rich S. The value of approved therapies for pulmonary arterial hypertension. Am. Heart J. 153(6), 889-890 (2007).
48. Peacock A, Naeije R, Galie N, Reeves JT. End points in pulmonary arterial hypertension: the way forward. Eur. Respir. J. 23(6), 947-953 (2004).
49. Hoeper MM, Oudiz RJ, Peacock A et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J. Am. Coll. Cardiol. 43(12 Suppl. S), S48-S55 (2004).
50. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333(4), 214-221 (1995).
51. Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159(6), 1925-1932 (1999).
52. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328(24), 1732-1739 (1993).
53. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327(2), 76-81 (1992).
54. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23), 3105-3111 (2005).
55. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173(9), 1023-1030 (2006).
56. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 22(2), 358-363 (2003).
57. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.Chest 130(1), 182-189 (2006).
58. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N. Engl. J. Med. 323(1), 27-36 (1990).
59. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. 338(5), 273-277 (1998).
60. Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med. 112(7), 485-491 (1990).
61. Rubin LJ. Primary pulmonary hypertension. N. Engl. J. Med. 336(2), 111-117 (1997).
62. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165(6), 800-804 (2002).
63. Tapson VF, Gomberg-Maitland M, McLaughlin VV et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129(3), 683-688 (2006).
64. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog. Cardiovasc. Dis. 45(3), 213-224 (2002).
65. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132(6), 425-434 (2000).
66. Farber HW, Graven KK, Kokolski G, Korn JH. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J. Rheumatol. 26(5), 1195-1196 (1999).
67. Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 113(1), 237-240 (1998).
68. Dorfmuller P, Humbert M, Perros F et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum. Pathol. 38(6), 893-902 (2007).
69. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288), 1119-1123 (2001).
70. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheum. Dis. 65(10), 1336-1340 (2006).
71. Girgis R, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in primary pulmonary hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J. Heart Lung Transplant. 24(10), 1626-1631 (2005).
72. Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169(4), 441-447 (2004).
73. Girgis RE, Frost AE, Hill NS et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann. Rheum. Dis. 66(11), 1467-1472 (2007).
74. Galie N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23), 3010-3019 (2008).
75. Badesch DB, Hill NS, Burgess G et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J. Rheumatol. 34(12), 2417-2422 (2007).
76. Adnot S. Lessons learned from cancer may help in the treatment of pulmonary hypertension. J. Clin. Invest. 115(6), 1461-1463 (2005).
77. Schermuly RT, Dony E, Ghofrani HA et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115(10), 2811-2821 (2005).
78. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol. Genomics 33(2), 278-291 (2008).
79. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 353(13), 1412-1413 (2005).
80. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann. Intern. Med. 145(2), 152-153 (2006).
81. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61(8), 736 (2006).
82. Carroll M, Ohno-Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCRABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90(12), 4947-4952 (1997).
83. Eddahibi S, Humbert M, Sediame S et al. Imbalance between platelet vascular endothelial growth factor and plateletderived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am. J. Respir. Crit. Care Med. 162(4 Pt 1), 1493-1499 (2000).
84. Grigoryev DN, Mathai SC, Fisher MR et al. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl. Res. 151(4), 197-207 (2008).
85. McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 174(11), 1257-1263 (2006).
86. Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 28(4), 691-694 (2006).
87. Simonneau G, Rubin LJ, Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med. 149(8), 521-530 (2008).
88. Mathai SC, Girgis RE, Fisher MR et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur. Respir. J. 29(3), 469-475 (2007).
89. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 24(6), 1007-1010 (2004).
90. Pietra GG, Edwards WD, Kay JM et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80(5), 1198-1206 (1989).
91. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70(4), 580-587 (1984).
92. Schachna L, Medsger TA Jr, Dauber JH et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 54(12), 3954-3961 (2006).